Log in

NASDAQ:HBIOHarvard Bioscience Stock Price, Forecast & News

$2.66
-0.03 (-1.12 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.59
Now: $2.66
$2.70
50-Day Range
$2.14
MA: $2.62
$2.89
52-Week Range
$1.39
Now: $2.66
$3.50
Volume94,643 shs
Average Volume166,241 shs
Market Capitalization$102.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Harvard Bioscience, Inc. provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion and temperature controllers, and microincubation and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions under the DSI and Buxco brands. It markets its products in approximately 100 countries through sales organizations, Websites, catalogs, and distributors to research scientists at pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Read More
Harvard Bioscience logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
Current SymbolNASDAQ:HBIO
CUSIP41690610
Phone508-893-8999

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$116.18 million
Cash Flow$0.33 per share
Book Value$2.15 per share

Profitability

Net Income$-4,690,000.00

Miscellaneous

Employees519
Market Cap$102.09 million
Next Earnings Date7/23/2020 (Estimated)
OptionableOptionable

Receive HBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.

Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions

How has Harvard Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Harvard Bioscience's stock was trading at $2.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HBIO stock has increased by 7.7% and is now trading at $2.66. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Harvard Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Harvard Bioscience.

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Harvard Bioscience.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its earnings results on Tuesday, May, 5th. The medical instruments supplier reported ($0.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.04. The medical instruments supplier earned $23.77 million during the quarter, compared to analyst estimates of $28 million. Harvard Bioscience had a negative net margin of 6.11% and a positive return on equity of 4.52%. View Harvard Bioscience's earnings history.

What price target have analysts set for HBIO?

2 equities research analysts have issued twelve-month price targets for Harvard Bioscience's stock. Their forecasts range from $2.00 to $4.00. On average, they expect Harvard Bioscience's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 12.8% from the stock's current price. View analysts' price targets for Harvard Bioscience.

Has Harvard Bioscience been receiving favorable news coverage?

Media coverage about HBIO stock has been trending very positive on Monday, according to InfoTrie. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Harvard Bioscience earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutHarvard Bioscience.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,100,000 shares, an increase of 79.1% from the April 30th total of 614,300 shares. Based on an average trading volume of 198,600 shares, the short-interest ratio is presently 5.5 days. Currently, 3.2% of the company's stock are short sold. View Harvard Bioscience's Current Options Chain.

Who are some of Harvard Bioscience's key competitors?

What other stocks do shareholders of Harvard Bioscience own?

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the following people:
  • Mr. Jeffrey A. Duchemin, CEO, Pres & Director (Age 53)
  • Ms. Kamalam Unninayar, Chief Financial Officer (Age 51)
  • Mr. Russell J. Sylvia, VP of Global HR
  • Mr. Corey Manchester, VP & Corp. Controller

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by many different retail and institutional investors. Top institutional shareholders include Engine Capital Management LP (9.98%), Granahan Investment Management Inc. MA (4.81%), Dalton Greiner Hartman Maher & Co. (4.22%), Acadian Asset Management LLC (2.79%), Invenomic Capital Management LP (1.28%) and Essex Investment Management Co. LLC (0.65%). Company insiders that own Harvard Bioscience stock include Bertrand Loy, James W Green, Jeffrey Duchemin, Katherine A Eade, Robert E Gagnon, Thomas W Loewald and Value Fund Lp Palogic. View institutional ownership trends for Harvard Bioscience.

Which major investors are selling Harvard Bioscience stock?

HBIO stock was sold by a variety of institutional investors in the last quarter, including Fondren Management LP, Essex Investment Management Co. LLC, Invenomic Capital Management LP, Two Sigma Investments LP, Squarepoint Ops LLC, Granahan Investment Management Inc. MA, State Street Corp, and Greenwood Capital Associates LLC. View insider buying and selling activity for Harvard Bioscience.

Which major investors are buying Harvard Bioscience stock?

HBIO stock was purchased by a variety of institutional investors in the last quarter, including Engine Capital Management LP, Globeflex Capital L P, Seizert Capital Partners LLC, Invesco Ltd., Wedge Capital Management L L P NC, Dalton Greiner Hartman Maher & Co., JPMorgan Chase & Co., and Acadian Asset Management LLC. Company insiders that have bought Harvard Bioscience stock in the last two years include Bertrand Loy, James W Green, Katherine A Eade, Thomas W Loewald, and Value Fund Lp Palogic. View insider buying and selling activity for Harvard Bioscience.

How do I buy shares of Harvard Bioscience?

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $2.66.

How big of a company is Harvard Bioscience?

Harvard Bioscience has a market capitalization of $102.09 million and generates $116.18 million in revenue each year. The medical instruments supplier earns $-4,690,000.00 in net income (profit) each year or $0.12 on an earnings per share basis. Harvard Bioscience employs 519 workers across the globe.

What is Harvard Bioscience's official website?

The official website for Harvard Bioscience is www.harvardbioscience.com.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.